Web17 mei 2024 · In the ICA’s view, Leadiant’s abusive strategy allowed it to charge excessively high prices that bore no reasonable relationship to the economic value of Leadiant CDCA, with the aim of gaining an undue economic advantage. Web8 aug. 2024 · The Netherlands Authority for the Consumer and Markets’ (“ACM“) announced focus on drug price developments has finally come to a tangible enforcement result: a fine of almost EUR 20 million imposed on Leadiant, …
Spain’s Antitrust Watchdog Fines Drugmaker For ‘Excessive’ Pricing
Web1 jun. 2024 · Adobe A ntitrust regulators in Italy have fined a drugmaker nearly $3.8 million for years of “excessive” price hikes on a rare disease medicine, the latest instance in which European... WebExcessive pricing and orphan drugs: Leadiant sanctioned by n the Italia Antitrust Authority . June 2024 . In a long-awaited decision published on 31 May 2024, the IAA found that … ian prouse
Leadiant wins suspension of Dutch ‘excessive pricing’ fine as …
Web25 sep. 2024 · 25 September 2024 On 6 September 2024, the Minister of Economy announced in a communication that a maximum price for Leadiant Biosciences' orphan drug, CDCA, which is used to treat the rare neurological disease, cerebrotendinous xanthomatosis (CTX), had been imposed. Web22 dec. 2024 · Spanish Competition Authority Set to Continue Excessive Pricing Probe Against Leadiant. 27/06/2024; Articles; On 15 June 2024, the Spanish competition authority (Comisión Nacional de los Mercados y la Competencia – CNMC) rejected the appeal by Leadiant Biosciences SpA, Leadiant Biosciences Ltd, Leadiant GmbH and Sigma Tau … Web31 aug. 2024 · Specifically, the ACM found that the prices Leadiant charged for its prescription drug CDCA-Leadiant were excessive, and the ACM imposed a fine on … ian prowse does this train stop on merseyside